XRAY Valuation

DENTSPLY SIRONA Inc

Add to Watchlist

Advanced Chart

13.910

+0.1(0.724%)1D

Overview
Forecast
Valuation
Earnings

XRAY Relative Valuation

XRAY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XRAY is overvalued; if below, it's undervalued.

Historical Valuation

DENTSPLY SIRONA Inc (XRAY) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.12 is considered Undervalued compared with the five-year average of 16.78. The fair price of DENTSPLY SIRONA Inc (XRAY) is between 32.70 to 47.88 according to relative valuation methord. Compared to the current price of 13.81 USD , DENTSPLY SIRONA Inc is Undervalued By 57.76%.

Relative Value

Fair Zone

32.70-47.88

Current Price：13.81

57.76%

Undervalued

7.12

Trailing

Forward

6.72

EV/EBITDA

DENTSPLY SIRONA Inc. (XRAY) has a current EV/EBITDA of 6.72. The 5-year average EV/EBITDA is 12.33. The thresholds are as follows: Strongly Undervalued below 6.76, Undervalued between 6.76 and 9.54, Fairly Valued between 15.12 and 9.54, Overvalued between 15.12 and 17.91, and Strongly Overvalued above 17.91. The current Forward EV/EBITDA of 6.72 falls within the Strongly Undervalued range.

8.39

EV/EBIT

DENTSPLY SIRONA Inc. (XRAY) has a current EV/EBIT of 8.39. The 5-year average EV/EBIT is 14.87. The thresholds are as follows: Strongly Undervalued below 8.71, Undervalued between 8.71 and 11.79, Fairly Valued between 17.95 and 11.79, Overvalued between 17.95 and 21.03, and Strongly Overvalued above 21.03. The current Forward EV/EBIT of 8.39 falls within the Strongly Undervalued range.

0.74

DENTSPLY SIRONA Inc. (XRAY) has a current PS of 0.74. The 5-year average PS is 2.03. The thresholds are as follows: Strongly Undervalued below 0.50, Undervalued between 0.50 and 1.27, Fairly Valued between 2.79 and 1.27, Overvalued between 2.79 and 3.55, and Strongly Overvalued above 3.55. The current Forward PS of 0.74 falls within the Undervalued range.

6.66

P/OCF

DENTSPLY SIRONA Inc. (XRAY) has a current P/OCF of 6.66. The 5-year average P/OCF is 14.76. The thresholds are as follows: Strongly Undervalued below 5.87, Undervalued between 5.87 and 10.32, Fairly Valued between 19.21 and 10.32, Overvalued between 19.21 and 23.65, and Strongly Overvalued above 23.65. The current Forward P/OCF of 6.66 falls within the Undervalued range.

7.80

P/FCF

DENTSPLY SIRONA Inc. (XRAY) has a current P/FCF of 7.80. The 5-year average P/FCF is 20.03. The thresholds are as follows: Strongly Undervalued below 6.23, Undervalued between 6.23 and 13.13, Fairly Valued between 26.92 and 13.13, Overvalued between 26.92 and 33.82, and Strongly Overvalued above 33.82. The current Forward P/FCF of 7.80 falls within the Undervalued range.

DENTSPLY SIRONA Inc (XRAY) has a current Price-to-Book (P/B) ratio of 1.40. Compared to its 3-year average P/B ratio of 1.85 , the current P/B ratio is approximately -24.00% higher. Relative to its 5-year average P/B ratio of 2.04, the current P/B ratio is about -31.12% higher. DENTSPLY SIRONA Inc (XRAY) has a Forward Free Cash Flow (FCF) yield of approximately 5.01%. Compared to its 3-year average FCF yield of 5.68%, the current FCF yield is approximately -11.81% lower. Relative to its 5-year average FCF yield of 5.44% , the current FCF yield is about -7.93% lower.

1.40

P/B

Median3y

1.85

Median5y

2.04

5.01

FCF Yield

Median3y

5.68

Median5y

5.44

Competitors Valuation Multiple

The average P/S ratio for XRAY's competitors is 2.31, providing a benchmark for relative valuation. DENTSPLY SIRONA Inc Corp (XRAY) exhibits a P/S ratio of 0.74, which is -67.85% above the industry average. Given its robust revenue growth of -4.88%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Inspire Medical Systems Inc

Performance Decomposition

Market capitalization of XRAY decreased by 47.69% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -0.41 to -4.70.

The secondary factor is the Revenue Growth, contributed -4.88%to the performance.

Overall, the performance of XRAY in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-4.88%

984.00M → 936.00M

Revenue Growth

1046.34%

-0.41 → -4.70

Margin Expansion

-1089.15%

0.29 → -2.90

P/E Change

-47.69%